에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APTO

MOMO

SPWH

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 헬로 그룹(NASDAQ:MOMO)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.

화요일 주목해야 할 주식: 헬로 그룹, Z스케일러, 앱토즈 그리고 2종목

Health Care

Movers

헬스에퀴티(NASDAQ:HQY)는 회사가 월요일 1분기 재무 결과를 발표한 후 주가가 상승했다. 이 보고서의 주요 내용을 살펴보자. 중요한 사항 (The Details): 헬스에퀴티는 분기별 주당 이익을 80센트로 보고했는데, 이는 애널리스트들의 합의 추정치인 66센트를 21.21% 상회했으며, 지난해 같은 기간보다 주당 이익인 50센트보다 60% 증가한 수치이다.

헬스에퀴티: 예상보다 좋은 제1분기 실적과 강력한 전망 발표 후 주가 상승

ADSK

LVRO

SAIC

YGMZ

월요일 아침(현지 시간) 미국 주식 선물이 상승면서, 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: Benzinga Pro의 데이터에 따르면 월스트리트는 사이언스 애플리케이션 인터내셔널(NYSE:SAIC)가 개장 전에 분기별 이익을 주당 1.92달러, 매출 18억 4천만 달러로 보고할 것으로 예상하고 있다. SAIC 주식은 시간외 거래에서 3.4% 상승한 139.20달러를 기록했다. 

사이언스 애플리케이션, 오토데스크 그리고 월요일 주목해야 할 주식 3종목

HealthEquity Inc

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

Government

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

WIIM

Health Equity shares are trading lower after the company reported worse-than-expected Q3 sales results.

JMP Securities analyst Constantine Davides maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Market Outperform and raises the price target from $105 to $107.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on HealthEquity, Raises Price Target to $107

RBC Capital analyst Sean Dodge maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $100 to $105.

RBC Capital Maintains Outperform on HealthEquity, Raises Price Target to $105

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/YEXT">third-quarter results</a>.
Yext reported quarterly earnings of 12 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $114.000 million which beat the analyst consensus estimate of $113.208 million.
Yext shares dipped 10.8% to $7.60 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Huize Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUIZ#NASDAQ">HUIZ</a>) shares fell 18.4% to $4.93 in pre-market trading after reporting third-quarter results.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares dipped 18.4% to $7.42 in pre-market trading after dipping 51% on Monday.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares dipped 9.4% to $7.04 in pre-market trading after jumping 26% on Monday.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares fell 8.8% to $16.90 in pre-market trading. The company announced a senior convertible notes offering amounting to $300 million with an option for an additional $45 million.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares fell 8.5% to $21.24 in pre-market trading.</li>
<li>HarborOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) shares fell 7.8% to $12.00 in pre-market trading.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares dipped 7.2% to $176.80 in pre-market trading as the company posted weaker-than-expected earnings and sales results for its second quarter.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) fell 6% to $95.00 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>Lufax Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LU#NASDAQ">LU</a>) declined 5.5% to $2.76 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42405361/sp-500-nasdaq-retreat-from-record-highs-investor-sentiment-declines-fear-greed-index-remains-in-neutral-zone">S&amp;P 500, Nasdaq Retreat From Record Highs As Nvidia Declines Over Chinese Antitrust Concerns: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

BILI

FLNC

HONE

HUIZ

ORCL

RADX

TIGR

YEXT

Yext, Oracle, Huize Holding And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

The Q3 earnings report for HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) was released on Monday, December 9, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into HealthEquity Q3 Earnings

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 5.0% increase share price change the next day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: HealthEquity Q3

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HealthEquity Earnings Analysis: Q3 Recap

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat on EPS by $0.16 which was followed by a 5.0% increase in the share price the next day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: HealthEquity Q3

The Q3 earnings report for HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) was released on Monday, December 9, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.16 which was followed by a 5.0% increase in the share price the next day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HealthEquity Q3 Earnings Assessment

Health Equity shares are trading lower after the company reported worse-than-expected Q3 sales results,

Guidance

Health Equity Sees FY26 Revenue $1.275B-$1.295B.

The earnings results for HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) for Q3 were made public on Monday, December 9, 2024 at 04:01 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 5.0% increase share price change the next day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HealthEquity Earnings Report: Q3 Overview

HealthEquity Sees FY25 Adj. EPS $3.08-$3.16 vs $3.11 Est; Revenue $1.185B-$1.195B Vs $1.184B Est.

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. The company reported quarterly sales of $300.400 million which missed the analyst consensus estimate of $305.343 million by 1.62 percent. This is a 20.54 percent increase over sales of $249.219 million the same period last year.

Earnings Beats

Earnings Misses

HealthEquity Q3 2025 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $300.400M Miss $305.343M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) is likely to report quarterly loss at $4.45 per share on revenue of $76.05 million. 
• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $29.20 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $366.41 million. 
<h3>Companies Reporting After The Bell</h3>
• Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) is projected to report quarterly earnings at $4.27 per share on revenue of $4.02 billion. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is estimated to report quarterly earnings at $4.34 per share on revenue of $3.17 billion. 
• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $495.72 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is likely to report quarterly loss at $4.98 per share on revenue of $251.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.11 per share on revenue of $9.03 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.29 per share on revenue of $106.00 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $290.00 million. 
• Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $23.75 million. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.48 per share on revenue of $14.11 billion. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is projected to report quarterly loss at $0.01 per share on revenue of $148.19 million. 
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $113.21 million. 
• C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) is expected to report quarterly loss at $0.16 per share on revenue of $91.02 million. 
• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is likely to report quarterly loss at $0.04 per share on revenue of $63.12 million. 
• Oil-Dri Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASYS

BRZE

CASY

GNSS

RENT

VBNK

Earnings Scheduled For December 9, 2024

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is preparing to release its quarterly earnings on Monday, 2024-12-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect HealthEquity to report an earnings per share (EPS) of $0.71.
HealthEquity bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.16, leading to a 5.13% increase in the share price the following trading session.
Here's a look at HealthEquity's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1733493625_0_0.png" alt="eps graph" />
<h3>Market Performance of HealthEquity's Stock</h3>
Shares of HealthEquity were trading at $100.845 as of December 05. Over the last 52-week period, shares are up 42.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on HealthEquity</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on HealthEquity.
Analysts have provided HealthEquity with 6 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $118.17, suggesting a potential 17.18% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Alignment Healthcare, Clover Health Investments and Progyny, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Alignment Healthcare is favoring an Buy trajectory, with an average 1-year price target of $12.5, suggesting a potential 87.6% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Clover Health Investments, with an average 1-year price target of $4.0, implying a potential 96.03% downside.</li>
<li>The consensus among analysts is an Neutral trajectory for Progyny, with an average 1-year price target of $21.0, indicating a potential 79.18% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Alignment Healthcare, Clover Health Investments and Progyny, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>23.15%</td>
<td>$204.05M</td>
<td>1.68%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>51.61%</td>
<td>$78.99M</td>
<td>-22.17%</td>
</tr>
<tr>
<td>Clover Health Investments</td>
<td>Neutral</td>
<td>8.16%</td>
<td>$81.21M</td>
<td>-2.74%</td>
</tr>
<tr>
<td>Progyny</td>
<td>Neutral</td>
<td>2.04%</td>
<td>$59.24M</td>
<td>2.34%</td>
</tr>
</tbody>
</table>

Key Takeaway:
HealthEquity ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.
<h3>Get to Know HealthEquity Better</h3>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Key Indicators: HealthEquity's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 23.15%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 11.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.68%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.06% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.54, HealthEquity adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/HQY/earnings">To track all earnings releases for HealthEquity visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into HealthEquity's Upcoming Earnings

Mizuho analyst Steven Valiquette initiates coverage on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform rating and announces Price Target of $126.

Initiation

Mizuho Initiates Coverage On HealthEquity with Outperform Rating, Announces Price Target of $126

In the last three months, 10 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $108.8, with a high estimate of $130.00 and a low estimate of $92.00. This current average has increased by 5.41% from the previous average price target of $103.22. 
<img src="https://www.benzinga.com/files/images/story/2024/1733162434_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Delving into HealthEquity's Background</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: HealthEquity displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 23.15%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 11.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): HealthEquity's ROE stands out, surpassing industry averages. With an impressive ROE of 1.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.06%, the company showcases effective utilization of assets.
Debt Management: HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For HealthEquity

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from $56 to $74. JP Morgan analyst Reginald Smith maintained an Overweight rating. Affirm shares closed at $70.01 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Tigress Financial boosted the price target for T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) from $235 to $280. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Kohl&#8217;s shares closed at $246.94 on Friday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research boosted HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $105 to $120. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares settled at $101.54 on Friday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital boosted Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) price target from $130 to $155. Loop Capital analyst Chris Dankert maintained a Buy rating. Emerson Electric shares closed at $132.60 on Friday. <a href="https://www.benzinga.com/quote/EMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $775 to $950. Evercore ISI Group analyst Mark Mahaney maintained an Outperform rating. Netflix shares closed at $886.81 on Friday.  <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) price target from $23 to $26. Deutsche Bank analyst Nate Svensson maintained a Buy rating on the stock. Flywire shares closed at $22.71 on Friday. See how other analysts view this stock.</li>
<li>UBS cut the price target for Applied Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from $13 to $2. UBS analyst Esther Rajavelu downgraded the stock from Buy to Neutral. Applied Therapeutics shares settled at $2.03 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) price target from $78 to $90. B of A Securities analyst Ebrahim Poonawala maintained a Buy rating. Citigroup shares closed at $70.87 on Friday. <a href="https://www.benzinga.com/quote/C/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein increased the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from $90 to $120. Bernstein analyst Harshita Rawat maintained an Outperform rating. Block shares closed at $88.55 on Friday. <a href="https://www.benzinga.com/quote/SQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) price target from $144 to $142. Deutsche Bank analyst Sidney Ho maintained a Buy rating. Dell shares closed at $127.59 on Friday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a></li>
</ul>

AFRM

APLT

DELL

FLYW

NFLX

TMUS

Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday

JMP Securities raised the firm's price target on HealthEquity (HQY) to $107 from $105 and keeps an Outperform rating on the shares. HealthEquity re...

HealthEquity price target raised to $107 from $105 at JMP Securities

RBC Capital analyst Sean Dodge raised the firm's price target on HealthEquity (HQY) to $105 from $100 and keeps an Outperform rating on the shares....

HealthEquity price target raised to $105 from $100 at RBC Capital

Analyst Alexander Paris of Barrington reiterated a Buy rating on Healthequity (HQY – Research Report), reducing the price target to $112.00. Alexan...

HealthEquity's Strong Q3 Performance and Revised Guidance Justify Buy Rating

Barrington analyst Alexander Paris lowered the firm's price target on HealthEquity (HQY) to $112 from $120 and keeps an Outperform rating on the sh...

HealthEquity price target lowered to $112 from $120 at Barrington

Healthequity Inc (HQY) has disclosed a new risk, in the Corporate Activity and Growth category. Healthequity Inc. is poised to undergo a critical l...

Leadership Change at Healthequity Inc.: Challenges and Risks as Scott Cutler Steps In as CEO

Bank of America Securities analyst Allen Lutz has reiterated their bullish stance on HQY stock, giving a Buy rating yesterday. Allen Lutz's rating ...

Positive Outlook for HealthEquity Amid Conservative Guidance and Market Expansion Opportunities

Allspring SMID Cap Growth Fund Q3 2024 Commentary

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on HQY stock, giving a Buy rating yesterday. Steven Valiquette has ...

Healthequity's Strong Performance and Promising Outlook Justifies Buy Rating

J.P. Morgan analyst Anne Samuel maintained a Buy rating on Healthequity (HQY – Research Report) on December 16 and set a price target of $110.00. T...

J.P. Morgan Sticks to Their Buy Rating for Healthequity (HQY)

J.P. Morgan's top Healthcare stocks for 2025

AXON

BILL

BPMC

CWAN

PTCT

TVTX

VRTX

XENE

Press Releases

New Research Findings Reveal Employers Who Contribute to HSAs See Double-Digit Growth in Employee Participation

HealthEquity Community Foundation Launches with Mission to Build Financial Literacy and Healthcare Confidence

New AI Tool Helps Americans Get Immediate, Helpful Answers to HSA and Consumer-Directed Benefits Questions

HealthEquity receives two top honors at the 19th Annual Golden Globee® Awards for Technology

HealthEquity Announces Third Quarter Earnings Release Date

Management

HealthEquity Announces Retirement of CEO Jon Kessler; Scott Cutler Appointed Successor

HealthEquity CMO Tia Padia Named "Visionary CMO" at MarCom Awards

HealthEquity 2025 Benefits Trends Unveiled: Cost Transparency and Containment Take Center Stage for Administrators

HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results

HealthEquity Caps 2024 With Widespread Recognition For Its Workplace Excellence

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

JMP Securities

RBC Capital

Mizuho

Barrington Research

Goldman Sachs

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 헬로 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.
2. 분석가들은 Z스케일러(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)가 5억 6,793만 달러의 매출과 주당 69센트의 분기 이익을 기록할 것으로 예상한다. 회사는 시장이 마감된 후 실적을 발표할 예정이다. Z스케일러의 주식은 시간외 거래에서 0.1% 상승한 200.00달러를 기록했다.
3. 앱토즈 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>)의 주식은 회사가 한미약품(Hanmi Pharmaceutical Co.)와의 시설 계약을 통해 1천만 달러의 대출을 발표한 후 금요일 애프터마켓에서 상승했다. 앱토즈의 주식은 애프터마켓에서 69.3% 급등하여 0.6874달러에 거래되고 있다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 시장이 마감된 후 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 매출 2억 8,487만 달러에 주당 70센트의 분기 이익을 게시할 것으로 예상된다. 헬스에퀴티의 주가는 시간외 거래에서 0.6% 하락한 79.10달러를 기록했다.
5. 애널리스트들은 스포츠맨스 웨어하우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>)가 마감 후 2억 8,503만 달러의 매출과 주당 9센트의 분기 손실을 보고할 것으로 예상한다. 스포츠맨스 웨어하우스의 주가는 시간외 거래에서 1% 하락한 2.08달러를 기록했다.
이것도 확인해 보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">이번 분기에 폭발적으로 성장할 수 있는 2개 부동산 주식</a></li>
</ul>
AI 도구를 사용하여 생성한 이미지
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 회사가 월요일 1분기 재무 결과를 발표한 후 주가가 상승했다. <a href="https://www.benzinga.com/pressreleases/24/06/g39145596/healthequity-reports-first-quarter-ended-april-30-2024-financial-results" target="_blank" rel="noopener">이 보고서</a>의 주요 내용을 살펴보자.
중요한 사항 (The Details): 헬스에퀴티는 분기별 주당 이익을 80센트로 보고했는데, 이는 애널리스트들의 합의 추정치인 66센트를 21.21% 상회했으며, 지난해 같은 기간보다 주당 이익인 50센트보다 60% 증가한 수치이다.
분기별 매출은 2억 8,760만 달러로 분석가 컨센서스 추정치인 2억 7,811만 달러를 넘어섰고, 이는 지난해 같은 기간의 매출 2억 4,443만 달러보다 17.66% 증가한 수치이다.
이 회사에 따르면 매출은 서비스 매출 1억1,820만 달러, 보관 매출 1억2,160만 달러, 교차 매출 4,770만 달러로 구성됐다. 2024년 4월 30일 현재 HSA는 910만 개로 전년 대비 13% 증가했으며, 여기에는 투자가 포함된 665,000개의 HSA가 포함되어 전년 대비 20% 증가했다. 2024년 4월 30일 기준 총 계정 수는 1,600만 개이며, 기타 소비자 지향 혜택 690만 개를 포함한다.
헬스에퀴티의 사장 겸 CEO인 존 케슬러(Jon Kessler)는 "기록적인 1분기 HSA 매출, 향상된 요금 적용 확대, 훌륭한 팀을 위한 베네핏월렛(BenefitWallet) 트랜치 3개 중 2개의 적시 전환이 2025 회계연도에 시작된다"고 말했다.
&#8220;성장과 마진 모두에 대한 추진력을 바탕으로 우리는 연간 지침을 높이고 놀라운 경험을 제공하고 파트너십을 심화하며 회원 성과를 높이기 위해 플랫폼 투자를 추진하고 있다.&#8221;
전망 (Outlook): 헬스에퀴티는 회계연도 이익을 주당 추정치 2.90달러 대비 주당 2.93~3.10달러로 전망하고, 회계연도 매출을 추정치 11억 6천만 달러 대비 11억 6천만~11억 8천만 달러로 예상한다.
HQY 주가 움직임: <a href="https://www.benzinga.com/stock/HQY#NASDAQ">Benzinga Pro</a>에 따르면, 이 회사의 주가는 월요일 시간외 거래에서 4.04% 상승한 84.50달러를 기록했다.

월요일 아침(현지 시간) 미국 주식 선물이 상승면서, 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 사이언스 애플리케이션 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>)가 개장 전에 분기별 이익을 주당 1.92달러, 매출 18억 4천만 달러로 보고할 것으로 예상하고 있다. SAIC 주식은 시간외 거래에서 3.4% 상승한 139.20달러를 기록했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)는 이사회 구성원인 엘리자베스 라파엘(Elizabeth Rafael)을 임시 CFO로 임명하고 1분기에 강력한 예비 결과를 발표했다. 이 회사는 시장 추정치인 주당 1.74달러에 비해 주당 1.87달러의 잠정 이익을 올렸고, 매출은 기대치인 13억 9,000만 달러에 비해 14억 2,000만 달러를 기록했다. 오토데스크의 주가는 시간외 거래에서 7.2% 상승한 216.04달러를 기록했다.</li>
<li>분석가들은 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)가 2억 7,811만 달러의 매출과 주당 66센트의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 실적을 발표할 예정이다. 헬스에퀴티의 주식은 시간외 거래에서 1.4% 상승한 82.79달러를 기록했다.</li>
</ul>
저희는 여기에서 <a href="https://www.benzinga.com/premarket/">개장 전 시장 정보를 확인하세요</a>
<ul>
<li>밍주 로지스틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>)는 옥실러스 글로벌(Oxylus Global) 인수에 합의했다고 발표했다. 밍주 로지스틱스의 주가는 시간외 거래에서 66.6% 급등한 0.5667달러를 기록했다.</li>
<li>분석가들은 라보로(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>)가 시장 마감 후 6억 1,907만 달러의 매출과 주당 3센트의 분기 이익을 기록할 것으로 예상합니다. 라보로의 주가는 시간외 거래에서 3.5% 하락한 5.77달러를 기록했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39111222/over-8m-bet-on-this-health-care-stock-check-out-these-4-stocks-insiders-are-buying">이 헬스케어 주식에 800만 달러 이상을 베팅하시겠습니까? 내부자들이 구매하고 있는 4가지 주식을 확인하세요.</a>

Comments

HealthEquity

뉴스

에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

화요일, 9월 03, 2024

월요일, 6월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌